Checkpoint Presentation_CKPT_Jan 2025.pdf

1、NASDAQ:CKPTCorporate PresentationJanuary 20252Checkpoint TherapeuticsSafe Harbor StatementThis presentation may contain“forward-looking statements”within the meaning of Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended.For such for

2、ward-looking statements,we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.Such statements include,but are not limited to,any statements relating to the timing and commercial launch and availability of UNLOXCYTT

3、M(cosibelimab-ipdl)for the treatment of adults with metastatic cutaneous squamous cell carcinoma(“cSCC”)or locally advanced cSCC who are not candidates for curative surgery or curative radiation,the commercial potential of UNLOXCYT,and anticipated healthcare professional and patient acceptance and u

4、se of UNLOXCYT for the FDA-approved indication,the potential differentiation of UNLOXCYT,including safety and the two-fold mechanism of action of UNLOXCYT,our growth strategy,products and product development programs and any other statements that are not descriptions of fact.Forward-looking statemen

5、ts are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business,operating results,financial condition and stock price.Factors that could cause our actual results to differ materially include the following:our ability to establish

6、and maintain a commercial infrastructure or to partner or license UNLOXCYT to a third-party with a commercial infrastructure;our,or our partner or licensees,ability to successfully launch,market and sell UNLOXCYT or future products,if approved;failure to obtain and maintain requisite regulatory appr